AlloVir Q1 net loss $43.9M; advances posoleucel to Phase 3 multi-virus prevention

Kalaris Therapeutics, Inc.

2023-Q1 EPS reported -$0.69

Net loss $43.9M ($0.69/share) vs $30.9M ($0.50) in Q1 2021; R&D spend $29.1M.
Cash, equivalents & marketable securities $201.4M, down from $248.1M at year-end 2021.
Initiated global Phase 3 registrational study of posoleucel to prevent 6 viruses in allo-HCT patients.
FDA granted third RMAT designation for posoleucel multi-virus prevention; estimated addressable population 40,000 patients/year.
FY2022 operating expense guidance reaffirmed at $130M–$145M excluding stock-based compensation.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.